Impact of Adjuvant Chemotherapy Cycles on Prognosis of Resectable Stomach Cancer: A Retrospective Analysis

Zhang, Wen-Ying; Zhang, Wen-Jun; Bai, Yu; Yuan, Hai-Hua; Liu, Feng; Gao, Jun; Gong, Yan-Fang; Jiang, Bin

추천

검색

자료유형: 학술저널

저자정보: Zhang, Wen-Ying (Department of Gastroenterology, Changhai Hospital, Second Military Medical University) Zhang, Wen-Jun (Department of Gerontology, Changhai Hospital, Second Military Medical University) Bai, Yu (Department of Gastroenterology, Changhai Hospital, Second Military Medical University) Yuan, Hai-Hua (Department of Oncology, No. 3 People's Hospital, School of Medicine, Shanghai Jiaotong University) Liu, Feng (Department of Oncology, No. 3 People's Hospital, School of Medicine, Shanghai Jiaotong University) Gao, Jun (Department of Gastroenterology, Changhai Hospital, Second Military Medical University) Gong, Yan-Fang (Department of Gastroenterology, Changhai Hospital, Second Military Medical University) Jiang, Bin (Department of Oncology, No. 3 People's Hospital, School of Medicine, Shanghai Jiaotong University)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제14권 제1호

발행연도: 2013.1

수록면: 381 - 386 (6page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Aims: The aim of this study was to investigate the effects of adjuvant chemotherapy cycles on the prognosis of patients with post-operative stomach cancer through retrospective analysis. Methods: A total of 128 patients with gastric cancer who underwent gastrectomy, followed by adjuvant chemotherapy consisting of epirubicin, cisplatin or oxaliplatin, leucovorin, and 5-fluorouracil, according to a defined schedule, were divided into three groups according to the number of chemotherapy cycles: Group I (<6 cycles); Group II (6 cycles); and Group III (>6 cycles). Results: The 5-year overall survival (OS) was 20.8% in Group I, 45.0% in Group II, and 42.9% in Group III, with a median follow-up of 43 months. The 5-year relapse-free survival (RFS) was 15.1% in Group I, 40% in Group II, and 40% in Group III. The OS and RFS in Groups II and III were significantly better than in Group I (OS, p = 0.002 and p=0.003; RFS, P<0.001 and P=0.002). There was no difference in OS (p = 0.970) or in RFS (p = 0.722) between Groups II and III. Multivariate Cox hazard analysis determined that the number of adjuvant chemotherapy cycles was an independent factor that influenced OS and RFS. Conclusion: Six cycles of adjuvant chemotherapy gave encouraging outcomes in patients with resectable gastric cancer. Further prospective randomized controlled investigations are warranted in a multi-center setting.

#Adjuvant chemotherapy #stomach cancer #gastrectomy

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요